A recent study indicates that people who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who stop traditional lifestyle programs.
Published data in a prominent medical journal demonstrates that while obese people can lose a large proportion of their body weight while using the jabs, the mass returns at an estimated rate of 0.8 kg per month after stopping.
"Users using such treatments must be informed of the potential of quick rebound weight gain when the treatment concludes," stated lead investigator Dr. Susan Jebb.
That rate of regain suggests a return to original mass in about 18 months.
Comparing Approaches
The research, which looked at dozens of studies involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with older methods.
Researchers note that people who lose weight through diet and exercise typically see a more gradual weight regain—around 100 grams monthly—after stopping.
The Reason for the Fast Regain
Nutrition scientists suggest the mechanism of the injections explains the amplified regain.
These medications imitate a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Long-term administration of GLP-1 concentrations far above than the body's typical production may cause the system to produce less of its own natural hormone, and could diminish responsiveness to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this GLP-1 'fix' results in appetite is uncontrolled, making binge eating a significant risk."
A Lifelong Disease?
Medical guidelines advise the jabs for individuals with weight-linked health risks, alongside recommended diet and exercise modifications.
A number of clinicians argue that, given the high risk of relapse, the therapy is often ongoing.
This view is reinforced by pharmaceutical companies, who say that the results "highlight the long-term nature of excess weight," comparing it to managing diseases like diabetes.
Patient Experiences
Individuals who have discontinued the jabs describe a sudden return of appetite.
"It was like something that goes on and I was suddenly extremely hungry," said an individual.
This challenge is compounded if patients have not adopted sustainable lifestyle or habit modifications during therapy.
Growing Adoption
Recent estimates indicate that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest remaining high.
- Adoption is more common among females compared to men.
- The 40s and 50s age group shows the greatest level of interest.
- Many obtain the drugs through private prescriptions rather than public health services.
In conclusion, experts caution that while GLP-1 drugs are powerful agents for weight loss, they are not a permanent cure and long-term success hinges on ongoing lifestyle support.
